EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Best Practices for the Nutritional Management of Infantile-Onset Lysosomal Acid Lipase Deficiency: A Case-Based Discussion

Fiona J White iD, Javier de Las Heras iD, Celia Rodríguez-Borjabad iD, Simon A Jones iD, Alexander Y Kim iD, Jenna Moore, Florian Abel, Laura Frank, Rosie Jones iD, Suresh Vijay

Nutrients · 2026

DOI: 10.3390/nu18020233 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Nutrients, 2026. Verfasst von Fiona J White und 9 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Medicine, St. Mary's Hospital, MFT, University of Manchester, Manchester M13 9WL, UK. Hauptthemen laut MEDLINE: Wolman Disease. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Kimberly MacKenzie, PhD, of Peloton Advantage, LLC, an OPEN Health company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infantile-onset lysosomal acid lipase deficiency (LAL-D) (Wolman disease, historically) is a rare inherited, rapidly progressive disorder caused by pathogenic variants in the LIPA gene, which encodes the enzyme LAL. LAL is essential for the metabolism of cholesteryl esters and triglycerides. LAL deficiency leads to the accumulation of cholesteryl esters and triglycerides within the lysosomes, macrophages, and parenchymal cells in most tissue types, including those in the liver, gastrointestinal tract, and lymph nodes but excluding the central nervous system. Infants with rapidly progressive LAL-D present with gastrointestinal disturbance, adrenomegaly with calcification, hepatosplenomegaly, growth failure due to malabsorption, and systemic inflammation. If untreated, rapidly progressive LAL-D typically leads to death within the first year of life. Treatment takes the two-pronged approach of sebelipase alfa, a human lysosomal acid lipase enzyme replacement therapy (ERT) that improves lipid metabolism, combined with nutritional management. Dietary substrate (lipid) reduction, known as substrate reduction therapy, is essential for optimal management in LAL-D. Following a nutritional plan and managing gastrointestinal disturbances together reduce systemic inflammation and improve growth, gut function, liver health, quality of life, and survival in patients with infantile-onset LAL-D. A multidisciplinary specialized team is necessary to manage the highly complex, multisystemic conditions in these patients. Nutritional management of LAL-D has evolved with increasing experience with the clinical management of ERT-treated infantile-onset LAL-D. A review of guidance for best practice nutritional management is needed. This narrative review aims to provide updated recommendations and guidance for the optimal nutritional management of infantile-onset LAL-D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wolman DiseaseHumansInfantSterol EsteraseEnzyme Replacement TherapyMaleFemale

Stichwörter der Autor:innen

LAL-DWolman diseasedietary substrate reductionearly diagnosisearly treatmentenzyme replacement therapyinfantile-onset lysosomal acid lipase deficiencymalabsorptionminimal lipid intakesebelipase alfasubstrate reduction therapy

Substanzen

Sterol EsteraseSebelipase alfa

Autor:innen und Institutionen

  • Genomic Medicine, St. Mary's Hospital, MFT, University of Manchester, Manchester M13 9WL, UK.
  • Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
  • Division of Pediatric Metabolism (CIBER-ER), Cruces University Hospital, 48903 Barakaldo, Spain.
  • Department of Pediatrics, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
  • Unitat de Nutrició i Unitat de Medicina Vascular i Metabolisme, Hospital Sant Joan de Reus, 43204 Reus, Spain.
  • Division of Genetics, Department of Medicine, Johns Hopkins All Children's Hospital, St. Petersburg, FL 33701, USA.

ORCID-Profile: Fiona J White, Javier de Las Heras, Celia Rodríguez-Borjabad, Simon A Jones, Alexander Y Kim, Rosie Jones

Förderung

  • Alexion, AstraZeneca Rare Disease
  • Kimberly MacKenzie, PhD, of Peloton Advantage, LLC, an OPEN Health company

Zitieren

APA

White, F. J., de Las Heras, J., Rodríguez-Borjabad, C., Jones, S. A., Kim, A. Y., Moore, J., Abel, F., Frank, L., Jones, R., & Vijay, S. (2026). Best Practices for the Nutritional Management of Infantile-Onset Lysosomal Acid Lipase Deficiency: A Case-Based Discussion. Nutrients. https://doi.org/10.3390/nu18020233

Vancouver

White FJ, de Las Heras J, Rodríguez-Borjabad C, Jones SA, Kim AY, Moore J, et al. Best Practices for the Nutritional Management of Infantile-Onset Lysosomal Acid Lipase Deficiency: A Case-Based Discussion. Nutrients. 2026. doi:10.3390/nu18020233

BibTeX
@article{White2026,
  author = {White, Fiona J and de Las Heras, Javier and Rodríguez-Borjabad, Celia and Jones, Simon A and Kim, Alexander Y and Moore, Jenna and Abel, Florian and Frank, Laura and Jones, Rosie and Vijay, Suresh},
  title = {Best Practices for the Nutritional Management of Infantile-Onset Lysosomal Acid Lipase Deficiency: A Case-Based Discussion},
  journal = {Nutrients},
  year = {2026},
  doi = {10.3390/nu18020233}
}
Kostenlos starten →